Пероральная химиотерапия винорелбином при распространенном раке молочной железы: ее роль в клинической практике


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Обоснование. В статье рассмотрены варианты ведения пациенток с метастатическим раком молочной железы в зависимости от характеристик опухоли, состояния пациентки, наличия сопутствующей патологии. Рассмотрены преимущества и особенности пероральной химиотерапии. Описание клинического случая. Описан клинический случай применения перорального винорелбина пациентками с раком левой молочной железы в реальной клинической практике. После пяти курсов неоадъювантной полихимиотерапии, дистанционной лучевой терапии на молочную железу, мастэктомии слева, адъювантной гормонотерапии тамоксифеном в послеоперационном периоде констатировано прогрессирование заболевания. Проведено лечение пероральным винорелбином. После достижения ремиссии пациентка переведена на поддерживающую терапию фулвестрантом. Заключение. В рамках вариантов лечения интерес вызывает использование препаратов пероральной химиотерапии, таких как капецитабин и пероральный винорелбин. Последние позволяют обеспечивать контроль болезни, обладают хорошей переносимостью и уменьшают время и затраты, связанные с лечением.

Полный текст

Доступ закрыт

Об авторах

Д. Д Сакаева

Республиканский клинический онкологический диспансер; Башкирский государственный медицинский университет

Email: d_sakaeva@mail.ru
кафедра фармакологии с курсом клинической фармакологии; д.м.н., зам. главного врача по химиотерапии 450054, Россия, Уфа, пр-кт Октября, 73/1

А. Ф Насретдинов

Республиканский клинический онкологический диспансер

Уфа, Россия

Список литературы

  1. Cardosos F., Costab A., Senkusd E., et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017;28-1:16-33. doi: 10.1093/annonc/mdw544.
  2. Cardosoa F., Costab A., Senkusd E., et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast. 2017;31:244-59. doi: 10.1016/j.breast.2016.10.001.
  3. Partridge A.H., Rumble R.B., Carey L.A., et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:3307-29. doi: 10.1200/JCO.2014.56.7479.
  4. Giordano S.H., Temin S., Kirshner J.J., et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:2078-99. doi: 10.1200/JCO.2013.54.0948.
  5. Finn R.S., Crown J.P., Lang I., et al. The cyclindependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet. Oncol. 2015;16:25-35.
  6. Seah D.S., Luis I.V., Macrae E., et al. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014;12:71-80.
  7. Dufresne A, Pivot X., Tournigand C., et al. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008;107:275-79.
  8. Dear R.F., McGeechan K., Jenkins M.C., et al. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2013;12:CD008792. doi: 10.1002/14651858.CD008792.pub2.
  9. Cardoso F., Bedard PL., Winer E.P., et al. ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: Combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101:1174-81. doi: 10.1093/jnci/djp235.
  10. Findlay M., von Minckwitz G., Wardley A. Effective oral chemotherapy for breast cancer: Pillars of strength. Ann Oncol. 2008;19:212-22.
  11. Liu G, Franssen E., Fitch M.I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110-15.
  12. Schott S., Schneeweiss A., Reinhardt J., et al. Acceptance of oral chemotherapy in breast cancer patients - a survey study. BMC. Cancer. 2011;11:129. doi: 10.1186/1471-2407-11129.
  13. Ruddy K., Mayer E., Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56-66. Doi: 10.3322/ caac.20004.
  14. Partridge A.H., Avorn J., Wang P.S., Winer E.P Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652-61.
  15. Goodin S., Griffith N., Chen B., et al. Safe handling of oral chemotherapeutic agents in clinical practice: Recommendations from an international pharmacy panel. J Oncol Pract. 2011;7:7-12.
  16. Blum J.L., Barrios C.H., Feldman N., et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2012;136:777-88. doi: 10.1007/s10549-012-2288-x.
  17. Aapro M., Finek J. Oral vinorelbine in metastatic breast cancer: A review of current clinical trial results. Cancer Treat Rev. 2012;38:120-26. doi: 10.1016/j.ctrv.2011.05.005.
  18. Oostendorp L.J., Stalmeier PF, Donders A.R., et al. Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: A systematic review. Lancet. Oncol. 2011;12:1053-61. doi: 10.1016/S1470-2045(11)70045-6.
  19. O'Shaughnessy J.A., Kaufmann M., Siedentopf F., et al. Capecitabine monotherapy: Review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist. 2012;17:476-84. doi: 10.1634/theoncologist.2011-0281.
  20. O'Shaughnessy J.A., Blum J., Moiseyenko V., et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol. 2001;12:1247-54.
  21. Stockler M.R., Harvey V.J., Francis P.A., et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol. 2011;29:4498-504. doi: 10.1200/JCO.2010.33.9101.
  22. Kaufmann M., Maass N., Costa S.D., et al. First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial. Eur J Cancer. 2010;46:3184-91. doi: 10.1016/j.ejca.2010.07.009.
  23. Robert N.J., Dieras V., Glaspy J., et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252-60. doi: 10.1200/JCO.2010.28.0982.
  24. Sparano J.A., Vrdoljak E., Rixe O., et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2010;28:3256-63. doi: 10.1200/JCO.2009.24.4244.
  25. Talbot D.C., Moiseyenko V., Van Belle S., et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer. 2002;86: 1367-72.
  26. [26] Brufsky A.M., Hurvitz S., Perez E., et al. RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for secondline treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011;29:4286-93. Doi: 10.1200/ JCO.2010.34.1255.
  27. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-99.
  28. Reichardt P., Von Minckwitz G., Thuss-Patience PC., et al. Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol. 2003;14:1227-33.
  29. Blum J.L., Jones S.E., Buzdar A.U., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485-93.
  30. Blum J.L., Dieras V., Lo Russo P.M., et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92:1759-68.
  31. Freyer G., Delozier T, Lichinister M., et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 2003;21:35-40.
  32. Amadori D., Koralewski P., Tekiela A., et al. Efficacy and safety of navelbine oral (NBVO) in first line metastatic breast cancer. Eur J Cancer. 2001;37(6):Abstract 713.
  33. Bartsch R., Pluschnig U., Wenzel C., et al. Oral vinorelbine in metastatic breast cancer: The Vienna experience. Ann Oncol. 2008;19(8):Abstract 160.
  34. Blancas I., Morales S., Diaz N., et al. Efficacy and safety of oral vinorelbine in first or second-line metastatic breast cancer. J Clin Oncol. 2010;28(15):Abstract 1090.
  35. Mansour M., Haddad N. Phase II study of single agent oral vinorelbine as a first line chemotherapy for metastatic breast cancer patients previousiy treated with adjuvant anthracyciines and/or taxanes. Proc 21st Internationai Congress on Anti Cancer Treatment. 2010. Abstract 627.
  36. Steger G.G., Dominguez A., Switsers O., et al. Phase II study evaiuating oral vinorelbine as a single-agent as first-line chemotherapy for metastatic breast cancer patients with bone metastases (NORBREAST-228 Trial): First efficacy results. Ann Oncol. 2014;25(4):Abstract 403P
  37. Tubiana-Mathieu N., Bougnoux P., Becquart D., et al. Aiiorai combination of oral vinorelbine and capecitabine as first-iine chemotherapy in HER2-negative metastatic breast cancer: An Internationai Phase II Trial. Br. J. Cancer. 2009;101:232-37. doi: 10.1038/sj.bjc.6605156.
  38. Noié F., Criveiiari D., Mattioii R., et al. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacoi. 2009;64:673-80. doi: 10.1007/s00280-008-0915-3.
  39. Campone M., Dobrovoiskaya N., Tjuiandin S., et al. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxei plus capecitabine in patients with metastatic breast cancer previousiy treated with anthracyciines. Breast J. 2013;19:240-49. doi: 10.1111/tbj.12098.
  40. Tawfik H., Rostom Y., Eighazaiy H. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2013;71:913-19. doi: 10.1007/s00280-013-2082-4.
  41. Finek J., Hoiubec L. Jr., Svoboda T., et al. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer Anticancer Res. 2009;29: 667-70.
  42. Deicambre C., Veyret C., Levy C., et al. A phase I/II study of capecitabine combined with oral vinorelbine as first or second iine therapy in iocaiiy advanced or metastatic breast cancer. Breast Cancer Res Treat. 2005;94(67): Abstract 1081.
  43. Jones A., O'Brien M., Sommer H., et al. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol. 2010;65:755-63. doi: 10.1007/s00280-009-1081-y.
  44. Lorusso V., Spada M., Giampagiia M., et al. oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncoiogico deli'Italia Meridionale). Ann Oncol. 2006;17:vii15-7.
  45. von Minckwitz G., du Bois A., Schmidt M., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A german breast group 26/breast international group 03-05 study. J Ciin Oncol. 2009;27:1999-2006. doi: 10.1200/JCO.2008.19.6618.
  46. Cameron D., Casey M., Press M., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112:533-43. doi: 10.1007/s10549-007-9885-0.
  47. Burstein H.J., Keshaviah A., Baron A.D., et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer. 2007;110:965-72.
  48. Andersson M., Lidbrink E., Bjerre K., et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study. J Ciin Oncol. 2011;29:264-71. doi: 10.1200/JCO.2010.30.8213.
  49. Bergen E., Berghoff A.S., Rudas M., et al. Taxanes plus trastuzumab compared to oral vinorelbine plus trastuzumab in HER2-overexpressing metastatic breast cancer. Breast Care (Basei). 2014;9:344-48. doi: 10.1159/000368330.
  50. Andersson M., Lopez-Vega J.M., Petit T., et al. Interim safety and efficacy of pertuzumab, trastuzumab and vinorelbine for first-line (1L) treatment of patients (pts) with HER2-positive iocaiiy advanced or metastatic breast cancer (MBC). Ann Oncol. 2014;25(4):Abstract 361PD.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2019

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах